Every 10-Q that ANTIAGING QNTUM LGN A (AAQL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AAQL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AAQL filings page.
Antiaging Quantum Living Inc. reported results for the three months ended June 30, 2026 that reflect a major shift in its business model and continued financial strain. Revenue rose to $730,117 from $291,438 a year earlier, driven entirely by proprietary health and beauty products and therapy services, after fully exiting legacy online platform services. Gross profit increased to $312,890, but gross margin fell sharply to 42.85% from 80.54% due to the move from high-margin platform services to inventory-based product sales.
Operating expenses grew to $635,966, mainly from higher rent and facility costs, leading to an operating loss of $323,076 and a net loss of $318,509, more than double the prior-year loss. Operating activities used $471,684 of cash, partially funded by $573,126 of new third-party borrowings. The company ended the quarter with $608,100 in cash, negative shareholders’ equity of $995,468, and a working capital deficit.
Management discloses substantial doubt about the company’s ability to continue as a going concern, citing ongoing losses, accumulated deficit of $2,565,867, and liquidity pressures. Operations rely heavily on loans from the majority shareholder and other lenders, and revenue is concentrated in a few customers and a single key supplier. Management also acknowledges material weaknesses in internal control over financial reporting, including limited U.S. GAAP expertise and inadequate segregation of duties, although it has begun efforts to improve controls.
Antiaging Quantum Living Inc. reported higher revenue but continued losses for the nine months ended December 31, 2025. Revenue rose to $1,021,894 from $529,714, mainly from technical operation support and maintenance services and initial activity at Anti-Aging Care LLC.
Gross profit increased to $763,117, but operating expenses of $1,224,781 led to a net loss of $467,138, narrower than the prior period’s $540,808. The company ended with a shareholders’ deficit of $300,616, cash of $936,910, and a working capital deficit of $113,526.
Management discloses substantial doubt about the ability to continue as a going concern, citing ongoing losses, an accumulated deficit of $1,876,850, and reliance on related-party funding, including $980,000 due to the president. During the period, $1,284,102 of promissory notes were converted into 4,280,340 Class A shares, reducing debt but increasing the share count to 34,275,340 as of February 13, 2026.
Antiaging Quantum Living Inc. (AAQL) reported its quarterly results for the period ended September 30, 2025. Six-month revenue reached $681,602, up from $375,243 a year ago, driven by technical operation support and maintenance services. Gross profit was $559,205 with an 82.04% gross margin. The company recorded a six-month net loss of $194,970, improving from a loss of $411,654.
For the latest quarter, revenue was $390,164 and net loss was $61,598. Cash and cash equivalents were $455,446 as of September 30, 2025, with working capital of $23,279. Management disclosed substantial doubt about continuing as a going concern due to ongoing losses, limited working capital, and reliance on external funding.
Financing relied on related parties: amounts due to related parties were $860,000, and non‑interest‑bearing promissory notes and loans to related parties totaled $1,698,330. Customer concentration was elevated, with 100% of six‑month revenue and accounts receivable from a single customer. Class A shares outstanding were 29,995,000 as of November 12, 2025.